Evogene Capital Surpluse from 2010 to 2024

EVGN Stock  USD 1.69  0.00  0.00%   
Evogene Capital Surpluse yearly trend continues to be very stable with very little volatility. Capital Surpluse is likely to drop to about 207.6 M. During the period from 2010 to 2024, Evogene Capital Surpluse quarterly data regression pattern had sample variance of 281 T and median of  186,268,000. View All Fundamentals
 
Capital Surpluse  
First Reported
2010-12-31
Previous Quarter
236.8 M
Current Value
207.6 M
Quarterly Volatility
16.8 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Evogene financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Evogene's main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.8 M, Interest Expense of 162.4 K or Selling General Administrative of 5.2 M, as well as many indicators such as Price To Sales Ratio of 63.47, Dividend Yield of 0.0 or PTB Ratio of 29.7. Evogene financial statements analysis is a perfect complement when working with Evogene Valuation or Volatility modules.
  
Check out the analysis of Evogene Correlation against competitors.
To learn how to invest in Evogene Stock, please use our How to Invest in Evogene guide.

Latest Evogene's Capital Surpluse Growth Pattern

Below is the plot of the Capital Surpluse of Evogene over the last few years. It is Evogene's Capital Surpluse historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Evogene's overall financial position and show how it may be relating to other accounts over time.
Capital Surpluse10 Years Trend
Slightly volatile
   Capital Surpluse   
       Timeline  

Evogene Capital Surpluse Regression Statistics

Arithmetic Mean193,770,332
Geometric Mean193,130,163
Coefficient Of Variation8.65
Mean Deviation14,045,065
Median186,268,000
Standard Deviation16,763,220
Sample Variance281T
Range56.6M
R-Value0.85
Mean Square Error82.6T
R-Squared0.73
Significance0.000054
Slope3,195,912
Total Sum of Squares3934.1T

Evogene Capital Surpluse History

2024207.6 M
2023236.8 M
2019205.9 M
2018187.7 M
2017186.3 M
2016183.3 M

About Evogene Financial Statements

Evogene investors utilize fundamental indicators, such as Capital Surpluse, to predict how Evogene Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Capital Surpluse236.8 M207.6 M

Pair Trading with Evogene

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Evogene position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Evogene will appreciate offsetting losses from the drop in the long position's value.

Moving together with Evogene Stock

  0.76FDMT 4D Molecular TherapeuticsPairCorr
  0.8JNJ Johnson Johnson Fiscal Year End 28th of January 2025 PairCorr
  0.87MRK Merck Company Fiscal Year End 6th of February 2025 PairCorr

Moving against Evogene Stock

  0.85BMY Bristol Myers Squibb Aggressive PushPairCorr
  0.78NAMS NewAmsterdam PharmaPairCorr
  0.6PHVS Pharvaris BVPairCorr
  0.52PMVP Pmv PharmaceuticalsPairCorr
  0.39ESLAW Estrella ImmunopharmaPairCorr
The ability to find closely correlated positions to Evogene could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Evogene when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Evogene - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Evogene to buy it.
The correlation of Evogene is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Evogene moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Evogene moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Evogene can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Evogene offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Evogene's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Evogene Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Evogene Stock:
Check out the analysis of Evogene Correlation against competitors.
To learn how to invest in Evogene Stock, please use our How to Invest in Evogene guide.
You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Evogene. If investors know Evogene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Evogene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(4.46)
Revenue Per Share
1.881
Quarterly Revenue Growth
0.398
Return On Assets
(0.28)
Return On Equity
(0.82)
The market value of Evogene is measured differently than its book value, which is the value of Evogene that is recorded on the company's balance sheet. Investors also form their own opinion of Evogene's value that differs from its market value or its book value, called intrinsic value, which is Evogene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Evogene's market value can be influenced by many factors that don't directly affect Evogene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Evogene's value and its price as these two are different measures arrived at by different means. Investors typically determine if Evogene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Evogene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.